APOBEC Mutagenesis: a novel Achilles heel of Breast cancer
The AMBER project aims to unravel APOBEC mutagenesis in breast cancer to identify prevention and treatment strategies, potentially transforming it into a targetable vulnerability.
Projectdetails
Introduction
APOBEC mutagenesis is a cellular mechanism by which genetic alterations are acquired somatically, driven by APOBEC enzyme family members. This mechanism is prominently observed in 15% of primary and 25% of recurrent breast cancer, the most common cause of cancer-related death in middle-aged women. Current evidence suggests APOBEC mutagenesis contributes to all disease stages, i.e., cancer initiation, progression, and treatment resistance.
Project Overview
The core idea of the AMBER project is that unraveling the mechanism of APOBEC mutagenesis induction and maintenance will turn this mechanism into breast cancer’s Achilles heel. To prove this, I will answer several challenging research questions:
- Why is APOBEC mutagenesis operational in breast cancer?
- How does APOBEC contribute to disease progression?
- Can we target APOBEC mutagenesis or APOBEC-driven tumors specifically?
Research Objectives
Epidemiological and Molecular Evidence
First, I will reveal epidemiological and molecular evidence for factors inducing APOBEC mutagenesis in breast cancer. This may help to prevent APOBEC mutagenesis from occurring, potentially decreasing breast cancer incidence.
Link to Disease Progression
Second, using global and single-cell genomics, I will secure a link between APOBEC mutagenesis and disease progression, giving leads to delay progression.
Targeting Vulnerabilities
Third, I will exploit a potential vulnerability of APOBEC-driven breast cancer, since I have found that these tumors may depend on a proficient homologous DNA repair (HR) pathway. When experimentally confirmed, targeting HR may extinguish APOBEC-driven disease.
Immune Response and Neo-epitopes
Finally, I have observed that APOBEC mutagenesis associates with a profound immune response. I hypothesize that this is due to a new type of neo-epitopes being produced. If proven true, targeting these neo-epitopes provides another effective means to eradicate APOBEC-driven tumors.
Conclusion
I am confident AMBER will provide the fundamental insights into APOBEC mutagenesis needed to turn it into an Achilles heel which may help to prevent, delay, or cure APOBEC-driven breast cancer.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.990 |
Totale projectbegroting | € 2.499.990 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancerThe ADRIP study aims to investigate the role of APOBEC3A in driving drug resistance and intra-tumoral heterogeneity in pancreatic cancer, with potential therapeutic implications. | ERC Starting... | € 1.880.615 | 2025 | Details |
Probing the malignant potential of mutant clones in healthy mammary tissue by successive mutagenesisSUCCESSion aims to develop a novel gene editing technology to study the impact of mutation order on pre-cancer evolution and environment rewiring, enhancing understanding and early intervention strategies for cancer. | ERC Starting... | € 1.497.740 | 2024 | Details |
Organ and mutation dependencies shaping the tumor microenvironmentThis project aims to analyze the tumor microenvironments of BRCA-driven cancers across four organs to identify common design principles for developing targeted therapies. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Targeting SWI/SNF-related chromatin remodelling defects in solid tumoursThis project aims to uncover and exploit synthetic lethal vulnerabilities in SWI/SNF-deficient tumours to enhance anti-tumour immune responses and develop novel immuno-oncology therapies. | ERC Starting... | € 1.499.887 | 2023 | Details |
Targeting the Polycomb Machinery in BAP1-related PathologiesThe T-BAP project aims to develop targeted compounds against PRC1.3/5 to restore normal H2Aub1 levels and create therapeutic strategies for cancers linked to BAP1 mutations. | ERC Proof of... | € 150.000 | 2024 | Details |
Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancer
The ADRIP study aims to investigate the role of APOBEC3A in driving drug resistance and intra-tumoral heterogeneity in pancreatic cancer, with potential therapeutic implications.
Probing the malignant potential of mutant clones in healthy mammary tissue by successive mutagenesis
SUCCESSion aims to develop a novel gene editing technology to study the impact of mutation order on pre-cancer evolution and environment rewiring, enhancing understanding and early intervention strategies for cancer.
Organ and mutation dependencies shaping the tumor microenvironment
This project aims to analyze the tumor microenvironments of BRCA-driven cancers across four organs to identify common design principles for developing targeted therapies.
Targeting SWI/SNF-related chromatin remodelling defects in solid tumours
This project aims to uncover and exploit synthetic lethal vulnerabilities in SWI/SNF-deficient tumours to enhance anti-tumour immune responses and develop novel immuno-oncology therapies.
Targeting the Polycomb Machinery in BAP1-related Pathologies
The T-BAP project aims to develop targeted compounds against PRC1.3/5 to restore normal H2Aub1 levels and create therapeutic strategies for cancers linked to BAP1 mutations.